GT Biopharma GTBP 深 滬
等待開盤 10-08 09:30:00 美东时间
6.20
-0.170
-2.67%
華盛通- 最 高6.47
- 今 開6.30
- 成交量 1.86万股
- 最 低 6.20
- 昨 收 6.37
- 總市值 1118.71万
- 52周最高 28.75
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 4.9101
- 委 比 88.77%
- 總股本 180.44万
- 歷史最高 14799.75
- 量 比 0.48
- 振 幅 4.24%
- 歷史最低 5.5525
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GT Biopharma Regains Nasdaq Minimum Bid Compliance
GT Biopharma ( ($GTBP) ) has provided an announcement. GT Biopharma, Inc., a Na...
09-26 04:54
GT Biopharma Restructures Capital via Series M Financing
GT Biopharma ( ($GTBP) ) has issued an update. On September 14, 2026, GT Biopha...
09-15 21:18
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
GT Biopharma will host a webinar on September 11, 2026, to discuss its TriKE® platform for cancer treatment. Michael Breen, CEO, and Dr. Jeffrey Miller will cover clinical progress in blood cancers and solid tumors, dose level insights, platform positioning, and future milestones. The webinar, titled "The TriKE® Platform, Clinical Progress, and the Case for NK Cell Immunotherapy," starts at 2:00 p.m. Eastern Time. Registration is available via th...
09-11 12:00
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure
GT Biopharma ( ($GTBP) ) just unveiled an update. On September 2, 2026, GT Biop...
09-04 00:20
GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55) per share from the same period last year.
08-14 20:29
GT Biopharma reports Q2 results
GT Biopharma press release (GTBP): Q2 net loss for the second quarter of 2026 of approximately $4.5 million, compared to $30.2 million for the same comparable quarter of 2025. The Company had cash and...
08-14 20:10
GT Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma reported second quarter 2026 financial results with a cash balance of $5.1 million, sufficient to fund operations through Q4 2026. The company has two TriKE® candidates in Phase 1 trials: GTB-3650 for CD33-positive leukemias and GTB-5550 for B7-H3-positive solid tumors, with updates expected in late 2026. GTB-5550 features subcutaneous dosing. Increased AI integration aims to advance multiple new candidates toward pre-IND development...
08-14 12:00
GT Biopharma Lowers Stockholder Quorum to One-Third
GT Biopharma ( ($GTBP) ) has provided an announcement. On June 8, 2026, GT Biop...
06-13 07:02
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.
06-01 19:31
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
GT Biopharma is leveraging AI-based tools to accelerate the development of tumor-targeting engagers and multi-domain proteins, reducing costs and reliance on trial-and-error experimentation. These technologies enhance binding, stability, and functional activity, shortening timelines and increasing the likelihood of translational success. The company expects multiple new development candidates to enter pre-IND development in 2027, with potential a...
06-01 12:00
